西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义

罗含欢, 师杰, 边巴扎西, 杨旭, 尼玛卓玛, 王倩, 李梅, 王寒, 廖瑞倩, 次仁曲珍

罗含欢, 师杰, 边巴扎西, 杨旭, 尼玛卓玛, 王倩, 李梅, 王寒, 廖瑞倩, 次仁曲珍. 西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义[J]. 协和医学杂志, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727
引用本文: 罗含欢, 师杰, 边巴扎西, 杨旭, 尼玛卓玛, 王倩, 李梅, 王寒, 廖瑞倩, 次仁曲珍. 西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义[J]. 协和医学杂志, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727
LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727
Citation: LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. DOI: 10.12290/xhyxzz.2021-0727

西藏地区藏族人群胃癌组织中H3K27me3表达水平及其临床意义

基金项目: 

西藏自治区自然科学基金组团式援藏医学项目 XZ2017ZR-ZY33

详细信息
    通讯作者:

    师杰, E-mail:shijie@pumch.cn

  • 中图分类号: R365

Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance

Funds: 

Tibet Natural Science Funding Committee Grant XZ2017ZR-ZY33

More Information
  • 摘要:
      目的  探究H3K27me3在西藏地区藏族人群胃癌组织中的表达水平及其与临床、病理特征的相关性。
      方法  回顾性收集2019年8月至2021年8月西藏自治区人民医院藏族胃癌患者及同期藏族非胃癌患者的临床与病理资料。采用免疫组化法检测胃癌患者手术切除的肿瘤组织、癌旁正常胃黏膜组织及非胃癌患者正常胃黏膜组织中H3K27me3表达情况,并比较不同临床与病理特征胃癌患者之间H3K27me3表达差异。
      结果  共入选符合纳入和排除标准的藏族胃癌患者54例,藏族非胃癌患者55例。H3K27me3定位于细胞核, 阳性表达时细胞核呈棕黄色颗粒状着色。胃癌组织中H3K27me3高表达率显著高于癌旁正常胃黏膜组织[64.8%(35/54)比29.6%(16/54),P<0.001]和非胃癌患者正常胃黏膜组织[64.8%(35/54)比34.5%(19/55),P=0.002],癌旁正常胃黏膜组织中H3K27me3高表达率与非胃癌患者正常胃黏膜组织无显著差异(P=0.683)。H3K27me3表达水平在不同年龄、性别及Lauren分型、分化程度、浸润深度、肿瘤最大径、TNM分期等胃癌患者之间均无显著差异(P均>0.05)。
      结论  西藏地区藏族人群胃癌组织中H3K27me3表达水平显著增高,暂未发现H3K27me3表达水平与藏族胃癌患者临床及病理特征具有相关性。
    Abstract:
      Objective  To investigate the expression and its significance of H3K27me3 in Tibetan patients with gastric cancer.
      Methods  Clinical and pathological data were retrospectively collected from Tibetan patients with gastric cancer in the Tibet Autonomous Region People's Hospital from August 2019 to August 2021 and Tibetan non-gastric cancer patients during the same period. The expression of H3K27me3 in gastric cancer tissues, corresponding adjacent normal gastric mucosa and normal gastric mucosa of Tibetan patients with non-gastric cancer tissues was detected by immunohistochemical method, and the differences of H3K27me3 expression between gastric cancer patients with different clinical and pathological characteristics was compared.
      Results  A total of 54 Tibetan gastric cancer patients and 55 Tibetan non-gastric cancer patients who met the inclusion and exclusion criteria were enrolled. H3K27me3 was localized in the nucleus, and the nucleus showed brownish-yellow granular staining when positively expressed. The high expression rate of H3K27me3 in gastric cancer tissues was significantly higher than that in adjacent normal gastric mucosa tissue[64.8%(35/54) vs. 29.6%(16/54), P < 0.001]and normal gastric mucosal tissue of Tibetan patients with non-gastric cancer[64.8%(35/54) vs. 34.5%(19/55), P=0.002], and the high expression rate of H3K27me3 in the adjacent normal gastric mucosa tissue was not significantly different from that in normal gastric mucosal tissue of Tibetan patients with non-gastric cancer(P=0.683). H3K27me3 expression in gastric cancer tissues was not related to gender, age, degree of differentiation, depth of invasion, maximum tumor size, Lauren's classification, lymph node metastasis, vascular and nerve invasion and TNM stage.
      Conclusions  H3K27me3 is highly expressed in gastric cancer tissues of Tibetan people in Tibet. There is no significant difference in H3K27me3 positive expression cells in adjacent tissues and normal gastric mucosa. The significance of H3K27me3 in Tibetan patients with gastric cancer is uncertain and requires further investigations.
  • 经过一天烈日的炙烤,住院部外面的地表温度已经高达40 ℃,进进出出需要加强监护的患者还在不断增加,面对监护室内堆积如山的病患,大家的心情已经烦躁不安。高速周转的病房似乎又经历了一波“大洗牌”,病床上躺着不同的面孔,交班正仔细且有序地进行着。“号外……又有新病人要从急诊科转入,目前鼻导管10 L/min吸氧中,呼吸困难,需要重新评估插管指征......”值班护士小罗一边接听着电话,一边冲大家喊道。此刻空气仿佛凝住了一般,最尴尬的事情莫过如此——在交班时要来病人。“大家先交班,速战速决,准备收病人......”作为今天当值的高年资主治医师,我立刻说道。

    伴随着转运车的声音,病人送来了,大家立刻围了上去,按照平时标准动作过床、吸氧、完成心电监护连接。我走到病床边,那是一位白发苍苍、胸前皮下还隐约有一枚“勋章”的爷爷,一看心电监护,我本能地反应那枚东西应该是心脏永久起搏器。为了判断病人意识及症状,我拍了拍老人肩膀,问道:“爷爷,您知道这是在哪儿吗?”老人没有回答,但是眼睛在不停地转动,嘴巴似乎要表达什么,带着一点儿北方口音,但听得不太清楚。我瞬时像明白了什么,于是俯下身去对着他的耳朵大声喊道:“爷爷,您知道这是在哪儿吗?您是不是听得不太清楚?”老人摇了摇头,又点了点头。

    此时,我身旁一位经验丰富的“老医生”冲我扬了扬手中的听诊器听筒,我第一反应是她要听诊,于是连忙说道:“我来吧。”但她却直接把听头给爷爷戴上了,并对着听筒大声说道:“老爷子,这样能听清吗?”老人喃喃地回答:“听清了,听清了……”慢慢地,他紧崩的神情似乎也逐渐舒展开来。经过一系列问诊和针对性的处理后,爷爷慢慢睡着了。

    病人急性呼吸窘迫的病因尚未完全明确,依然有病情随时加重的危险,依照惯例,我们立即联系家属了解老人的病史并进行谈话签字。通过与家属充分沟通,我们了解到了爷爷的慢性病史以及本次发病的诱因,还得知爷爷听力不好,这几天辗转各大医院,一直没休息好,病情也越来越重了。好在经过我们悉心的治疗和照顾,两周后爷爷终于出院了!

    门诊复诊时,我看到爷爷耳朵上多了一副助听器,便打趣道:“爷爷,现在声音清楚多了吧?”爷爷笑着回答:“这玩意儿还是没有你们给我戴的东西听得清楚。”我和家属听完都哈哈大笑起来……

    后记

    听诊器的发明已有近200年的历史,其除了可以帮助医生完成重要的听诊检查外,在某些情况下还可以成为与病人沟通的桥梁。从法国医生雷奈克为了诊治患者,第一次提出“听诊器”的概念,到吴孟超院士在冬天查房时先用双手捂热听诊器再为患者听诊,再到为了能让患者听清楚,发现听诊器的新用途……不同听诊器的故事中,有不同的主人公以及不同的场景,但伴随的都是那份来自医生的爱,那份给予患者温暖的爱。病人与医生之间的第一步,是沟通,是了解,但病人在任何时候和任何状态下,都一定是需要帮助的那个人。任何人在面对身体的病痛时,或是因为没有足够专业的知识,或是因为疾病带来的切肤之痛,无论是酸胀、麻木、疼痛、无力,还是其他任何一种异样的感觉,都会让其内心产生对于异常表现的无限猜测以及随之而来的焦虑、恐慌。初入医学院时的我,心里想的只是如何掌握高精尖的各种医学技术,如何把病看好。进入医院工作多年以后,特别是在经历新型冠状病毒感染疫情后,我深切地体会到,不管医生的技术有多精湛,医疗水平有多高超,医生的关怀和援助永远都是病人最坚实的情感堡垒。治病一定是依靠科学,但让病人感觉到舒服却更需要医生对于患者那颗帮助的心。从医和患这层关系构建起来的那一刻起,他们就不该是对立的,而是共生的,更是共情的,感同身受、同气连枝才是医治疾病的起点,更是每一个合格医生毕生追求的终点。

    临床医生正如其名字一样,需要站在床边仔细观察病人。观察的目的除正确诊断病情外,更重要的是察觉病人最需要的帮助是什么。故事中的老人一直处于听不清周围声音的状态,这时候病人可能会感到恐惧与烦躁,甚至会导致病情恶化,而一次仔细的观察就能够使问题迎刃而解。一个小小的听诊器,以及听诊器带来的这份“逆向思维”,彰显的不仅是一种临床采集病史的技巧,更是医生把心打开,试图去侧耳倾听病人诉说的耐心,以及尽其所能去关爱病人的慈悲。

    因此,听诊器的故事,讲述的不是一种疾病的诊断,更不是一个病例的转归,听诊器联通的亦非症状与诊断,心跳与鼓膜,而是受伤的心和呵护的手,告诉我你哪里不舒服,我一定会想办法听到你的诉说,也一定会陪着你直到疾病消散。把痛苦告诉我,把希望传给你,这才是听诊器的真正意义所在,才是医生和病人最正确的相处方式。一如美国医生特鲁多对医生这个职业的经典描述——有时是治愈,常常是帮助,总是去安慰!

    作者贡献:罗含欢负责试验设计、免疫组化结果判读及论文撰写;师杰负责免疫组化结果判读和论文修订;杨旭进行数据统计学分析;边巴扎西、尼玛卓玛、王倩、王寒、廖瑞倩、次仁曲珍、李梅负责临床病理资料收集、免疫组化制片。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1   H3K27me3蛋白在胃癌组织中表达的免疫组化图(EnVision, ×200)

    A.高表达;B.低表达

    图  2   H3K27me3蛋白在癌旁正常胃黏膜组织中表达的免疫组化图(EnVision,×100)

    A. 高表达;B. 低表达

    图  3   H3K27me3蛋白在非胃癌患者正常胃黏膜组织中表达的免疫组化图(EnVision,×100)

    A. 高表达;B. 低表达

    表  1   不同临床与病理特征西藏地区藏族胃癌患者H3K27me3表达情况比较[n(%)]

    指标 低表达(n=19) 高表达(n=35) P
    年龄 0.128
      ≤60岁 16(84.2) 22(62.9)
      >60岁 3(15.8) 13(37.1)
    性别 >0.999
      男 13(68.4) 24(68.6)
      女 6(31.6) 11(31.4)
    Lauren分型 0.723
      肠型 6(31.6) 15(42.9)
      弥漫型 7(36.8) 11(31.4)
      混合型 6(31.6) 9(25.7)
    分化程度 0.388
      中-高分化 10(52.6) 13(37.1)
      低分化 9(47.4) 22(62.9)
    浸润深度 0.506
      pT1+pT2 6(31.6) 7(20.0)
      pT3+pT4 13(68.4) 28(80.0)
    肿瘤最大径 0.263
      ≤4 cm 6(31.6) 17(48.6)
      >4 cm 13(68.4) 18(51.4)
    脉管侵犯 0.577
      是 7(36.8) 16(45.7)
      否 12(63.2) 19(54.3)
    神经侵犯 0.760
      是 11(57.9) 23(65.7)
      否 8(42.1) 12(34.3)
    淋巴结转移 0.534
      是 12(63.2) 26(74.3)
      否 7(36.8) 9(25.7)
    TNM分期 0.394
      Ⅰ~Ⅱ期 11(57.9) 15(42.9)
      Ⅲ~Ⅳ期 8(42.1) 20(57.1)
    下载: 导出CSV
  • [1]

    Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. DOI: 10.3322/caac.21660

    [2] 旦增, 李康, 王中华, 等. 拉萨地区社区人群的胃癌流行病学特征[J]. 世界华人消化杂志, 2013, 21: 2104-2108. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201321029.htm

    Dan Z, Li K, Wang ZH, et al. Epidemiological features of gastric cancer in a community population in Lhasa[J]. Shijie Huaren Xiaohua Zazhi, 2013, 21: 2104-2108. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201321029.htm

    [3]

    Kurdistani SK. Histone modifications in cancer biology and prognosis[J]. Prog Drug Res, 2011, 67: 91-106.

    [4]

    Bates SE. Epigenetic Therapies for Cancer[J]. N Engl J Med, 2020, 383: 650-663. DOI: 10.1056/NEJMra1805035

    [5]

    Xiao W, Zhou Q, Wen X, et al. Small Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy[J]. Front Pharmacol, 202, 12: 702360.

    [6]

    Nam NH, Huong TL, Dung do TM, et al. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents[J]. Eur J Med Chem, 2013, 70: 477-486. DOI: 10.1016/j.ejmech.2013.10.045

    [7]

    Luu T, Frankel P, Beumer J H, et al. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial[J]. Cancer Chemother Pharmacol, 2019, 84: 1201-1208. DOI: 10.1007/s00280-019-03955-7

    [8]

    Imai Y, Hirano M, Kobayashi M, et al. HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action[J]. Cancers (Basel), 2019, 11: 475. DOI: 10.3390/cancers11040475

    [9]

    Zang H, Qian G, Zong D, et al. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat(LBH589)[J]. Cancer, 2020, 126: 2024-2033. DOI: 10.1002/cncr.32744

    [10]

    Tanimoto A, Takeuchi S, Arai S, et al. Histone deacety-lase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-Mutant lung cancer[J]. Clin Cancer Res, 2017, 23: 3139-3149. DOI: 10.1158/1078-0432.CCR-16-2271

    [11]

    Zhang L, Zhong K, Dai Y, et al. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients[J]. J Gastroenterol, 2009, 44: 305-312. DOI: 10.1007/s00535-009-0027-9

    [12]

    Huang H, Xie L, Feng X, et al. An integrated analysis of DNA promoter methylation, microRNA regulation, and gene expression in gastric adenocarcinoma[J]. Ann Transl Med, 2021, 9: 1414. DOI: 10.21037/atm-21-3211

    [13]

    Li Y, Guo D, Sun R, et al. Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate with Patient Outcome in Gastric Cancer[J]. Dig Dis Sci, 2019, 64: 439-446. DOI: 10.1007/s10620-018-5341-8

    [14]

    WHO Classification Tumours Editorial Board. WHO classification of tumours of digestive system[M]. Lyon: LARC Press, 2019.

    [15]

    Samal S, Patnaik A, Sahu F, et al. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas-prognostic biomarkers for routine practice[J]. Folia Neuropathol, 2020, 58: 133-142. DOI: 10.5114/fn.2020.96970

    [16] 高福利, 吕瑛, 曹俊, 等. H3K27me3在胃癌中的表达及其临床意义[J]. 世界华人消化杂志, 2011, 19: 3597-3602. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201135013.htm

    GaoFL, LYU Y, Cao J, et al. Significance of H3K27me3 expression in gastric cancer[J]. Shijie Huaren Xiaohua Zazhi, 2011, 19: 3597-3602. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201135013.htm

    [17]

    He LJ, Cai MY, Xu GL, et al. Prognostic significance of overexpression of EZH2 and H3K27me3 proteins in gastric cancer[J]. Asian Pac J Cancer Prev, 2012, 13: 3173-3178. DOI: 10.7314/APJCP.2012.13.7.3173

    [18] 高恩惠, 刘丹, 陈洁, 等. H3K27me3在肿瘤中的表达及其应用[J]. 中国新药与临床杂志, 2021, 40: 406-410. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202106002.htm

    Gao EH, Liu D, Chen J, et al. Expression of H3K27me3 in tumors and its application[J]. Zhongguo Xinyao Yu Linchuang Zazhi, 2021, 40: 406-410. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202106002.htm

    [19]

    Hong F, Zhao M, Zhang L, et al. Inhibition of Ezh2 in vitro and the decline of Ezh2 in developing midbrain promote dopami-nergicneurons differentiation through modifying H3K27me3[J]. Stem Cells Dev, 2019, 28: 649-658. DOI: 10.1089/scd.2018.0258

    [20] 张宁, 曾智, 阎丽萍, 等. 幽门螺杆菌感染与胃癌中PRC2和H3K27me3的表达关系[J]. 临床研究与应用杂志, 2018, 45: 667-672. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201813006.htm

    Zhang N, Zeng Z, Yan LP, et al. Relationship between Helicobacter pylori infection and the expression of PRC2 and H3K27me3 in gastric cancer[J]. Linchuang Yanjiu Yu Yingyong Zazhi, 2018, 45: 667-672. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201813006.htm

  • 期刊类型引用(2)

    1. 殷晓玉,蒋诗萌,王军. 辅助技术在智能可穿戴设备中的研究进展. 毛纺科技. 2024(05): 127-133 . 百度学术
    2. 冯郑文,胡永强,朱宸立,李海瑾,李卉,杜娟. 国外基层老年人辅助技术服务开展现状及对我国的启示. 中华全科医师杂志. 2024(07): 752-757 . 百度学术

    其他类型引用(1)

图(3)  /  表(1)
计量
  • 文章访问数:  371
  • HTML全文浏览量:  113
  • PDF下载量:  17
  • 被引次数: 3
出版历程
  • 收稿日期:  2021-11-01
  • 录用日期:  2021-12-12
  • 刊出日期:  2022-11-29

目录

    /

    返回文章
    返回
    x 关闭 永久关闭